Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

A retrospective study of 81 patients treated with valproate, valpromide and substained-release valproate (CROSBI ID 546183)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Cvitanović-Šojat, Ljerka ; Mucić-Pucić, Branka ; Šepić Grahovac, Dubravka ; Hajnzić, Tomislav-Franjo ; Mataija, Marina A retrospective study of 81 patients treated with valproate, valpromide and substained-release valproate // Abstracts. Bielefeld: Bethel - Cleveland Clinic, 1999. str. 42-x

Podaci o odgovornosti

Cvitanović-Šojat, Ljerka ; Mucić-Pucić, Branka ; Šepić Grahovac, Dubravka ; Hajnzić, Tomislav-Franjo ; Mataija, Marina

engleski

A retrospective study of 81 patients treated with valproate, valpromide and substained-release valproate

A retrospective study of 81 patients (PTS) treated with sodium valproate (VPA, Na di-n-propylacetat, Apilepsin) was done. All children had been using VPA as monotherapy or add-on therapy for at least 6 months to five years. The daily dosage was 300 to 1200 mg. Between 74 PTS receiving enteric-coated tablets, aged 3 to 16 years, 52.7% had primary generalized epilepsy and 47, 3% had complex partial seizures that did or did not secondary generalize. Because of the cost of VPA enteric-coated tablets, during 1991/92 in 69 PTS valpromide (VPD, diropylacetamide, Diprozin) was administrated and was free of charge. In 5 schoolchildren sustained-release VPA (SR-VPA, Depakine CR, Orfiril RT) was administrated and paid by the parents. Our retrospective study of 74 PTS led to the following conclusions: PTS with VPA formulation could immediately change to the same daily dosage of VPD or SR-VPA without loss of seizure control. After the change of VPA formulation side effects was not seen. Valproate plasma levels were the same after the administration of VPD and SR-VPA. There was no change in the plasma levels of the other antiepileptic drugs in patients receiving polytherapy. The advantage of SR-VPA is the administration of a single evening dose, but this form is not available in Croatia.

Epilepsy; Sodium valproate; Valpromide; Substained-release valproate

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

42-x.

1999.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Abstracts

Bielefeld: Bethel - Cleveland Clinic

Podaci o skupu

10th International Bethel-Cleveland Clinic Epilepsy Symposium

poster

14.04.1999-18.04.1999

Bielefeld, Njemačka

Povezanost rada

Kliničke medicinske znanosti, Farmacija